Timothy Best

720 total citations
22 papers, 200 citations indexed

About

Timothy Best is a scholar working on Oncology, Pathology and Forensic Medicine and Epidemiology. According to data from OpenAlex, Timothy Best has authored 22 papers receiving a total of 200 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 7 papers in Pathology and Forensic Medicine and 6 papers in Epidemiology. Recurrent topics in Timothy Best's work include CAR-T cell therapy research (9 papers), Lymphoma Diagnosis and Treatment (7 papers) and Cytomegalovirus and herpesvirus research (4 papers). Timothy Best is often cited by papers focused on CAR-T cell therapy research (9 papers), Lymphoma Diagnosis and Treatment (7 papers) and Cytomegalovirus and herpesvirus research (4 papers). Timothy Best collaborates with scholars based in United States, United Kingdom and Canada. Timothy Best's co-authors include Andrew D. Skol, David V. Conti, Wendy Cozen, Thomas M. Mack, Louise C. Strong, Kenan Onel, Leslie L. Robison, M. H. Finlayson, Yutaka Yasui and Sarah A. Jackson and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Timothy Best

17 papers receiving 192 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Timothy Best United States	7	55	44	39	38	34	22	200
Francesco Saglio Italy	9	91 1.7×	51 1.2×	15 0.4×	36 0.9×	35 1.0×	24	258
Juliana Folloni Fernandes Brazil	6	50 0.9×	34 0.8×	9 0.2×	26 0.7×	34 1.0×	19	211
Luc Matthieu Fornecker France	9	91 1.7×	48 1.1×	64 1.6×	27 0.7×	31 0.9×	17	305
Ghanim Khatib Türkiye	11	42 0.8×	53 1.2×	26 0.7×	40 1.1×	27 0.8×	49	349
Ben Carpenter United Kingdom	11	160 2.9×	44 1.0×	27 0.7×	30 0.8×	27 0.8×	28	320
Hakan Koç Türkiye	10	96 1.7×	75 1.7×	21 0.5×	27 0.7×	56 1.6×	38	369
P.S.R.K. Sastry India	8	71 1.3×	18 0.4×	31 0.8×	31 0.8×	42 1.2×	27	245
Ryoko Yamasaki Japan	11	116 2.1×	67 1.5×	35 0.9×	40 1.1×	37 1.1×	33	314
Katrin Hebel Germany	9	34 0.6×	31 0.7×	13 0.3×	51 1.3×	14 0.4×	11	306
H. Tai Japan	9	58 1.1×	60 1.4×	20 0.5×	49 1.3×	38 1.1×	12	320

Countries citing papers authored by Timothy Best

Since Specialization

Citations

This map shows the geographic impact of Timothy Best's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timothy Best with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timothy Best more than expected).

Fields of papers citing papers by Timothy Best

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timothy Best. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timothy Best. The network helps show where Timothy Best may publish in the future.

Co-authorship network of co-authors of Timothy Best

This figure shows the co-authorship network connecting the top 25 collaborators of Timothy Best. A scholar is included among the top collaborators of Timothy Best based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Timothy Best. Timothy Best is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Oluwole, Olalekan O., Sally W. Wade, Nathaniel Smith, et al.. (2025). Short-Term Costs Associated with Outpatient Use of Axicabtagene Ciloleucel in Second-Line Relapsed/Refractory Large B-Cell Lymphoma Based on Zuma-24 Clinical Trial. Transplantation and Cellular Therapy. 31(2). S399–S400.

Charles, Oscar, Ben Margetts, John Booth, et al.. (2025). Defining a CMV viral load threshold for pre‐emptive therapy in paediatric haematopoietic stem cell transplant recipients. British Journal of Haematology. 207(3). 911–919.

Gribben, John G., Emmanuel Bachy, Kathleen Beusterien, et al.. (2025). Patient and physician treatment preferences in relapsed/refractory follicular lymphoma: a discrete choice experiment in the United States, United Kingdom, France, Germany, Brazil, and Japan. Frontiers in Oncology. 15. 1589722–1589722.

Venturini, Cristina, Julia Colston, Oscar Charles, et al.. (2024). Persistent Low-Level Variants in a Subset of Viral Genes Are Highly Predictive of Poor Outcome in Immunocompromised Patients With Cytomegalovirus Infection. The Journal of Infectious Diseases. 230(2). e427–e436. 1 indexed citations

Bhaskar, Shakthi, Babatunde Adedokun, Olalekan O. Oluwole, et al.. (2024). Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) in the US: A CIBMTR Report. Blood. 144(Supplement 1). 527–527. 2 indexed citations

Hatcher, James, Timothy Best, Marios Kaliakatsos, et al.. (2024). Increasing Number of Clinically Severe Mycoplasma pneumoniae Infections in Children After the COVID-19 Pandemic: A Single-Center Case Series. Journal of the Pediatric Infectious Diseases Society. 14(1). 1 indexed citations

Kanters, Steve, Sara Beygi, Timothy Best, et al.. (2024). Matching-Adjusted Indirect Comparisons of Axicabtagene Ciloleucel to Mosunetuzumab for the Treatment of Relapsed/Refractory Follicular Lymphoma. Transplantation and Cellular Therapy. 30(9). 885.e1–885.e11. 2 indexed citations

Kreins, Alexandra Y., Juanita Pang, Oscar Charles, et al.. (2024). Favipiravir induces HuNoV viral mutagenesis and infectivity loss with clinical improvement in immunocompromised patients. Clinical Immunology. 259. 109901–109901. 4 indexed citations

Locke, Frederick L., et al.. (2024). A United States (US) Cost-Effectiveness Analysis of Axicabtagene Ciloleucel Compared to Odronextamab in Third Line or Later (3L+) Diffuse Large B-Cell Lymphoma. Blood. 144(Supplement 1). 7592–7592.

10.

Ray, M. D., Steve Kanters, Sara Beygi, et al.. (2023). Matching‐adjusted indirect comparison of axicabtagene ciloleucel versus mosunetuzumab in relapsed/refractory follicular lymphoma patients after 2 prior systemic treatments. Hematological Oncology. 41(S2). 522–523. 3 indexed citations

11.

Jacobson, Caron A., Michael Hemmer, Zhen‐Huan Hu, et al.. (2023). S223: REAL-WORLD EARLY OUTCOMES OF AXICABTAGENE CILOLEUCEL FOR RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA. HemaSphere. 7(S3). e31464ce–e31464ce. 1 indexed citations

12.

Wang, Hailin, Jiali Yan, Alex F. Herrera, et al.. (2023). Comparative Effectiveness of Axicabtagene Ciloleucel Vs Historical Standard-of-Care in Patients with Relapsed or Refractory Follicular Lymphoma: An Analysis of CIBMTR and SCHOLAR-5 Data. Blood. 142(Supplement 1). 2121–2121. 1 indexed citations

13.

Jacobson, Caron A., Michael Hemmer, Zhen‐Huan Hu, et al.. (2023). Real-world early outcomes of axicabtagene ciloleucel for relapsed or refractory (R/R) follicular lymphoma (FL).. Journal of Clinical Oncology. 41(16_suppl). 7509–7509. 9 indexed citations

14.

Houldcroft, Charlotte J., Sunando Roy, Ben Margetts, et al.. (2021). Using Whole Genome Sequences to Investigate Adenovirus Outbreaks in a Hematopoietic Stem Cell Transplant Unit. Frontiers in Microbiology. 12. 667790–667790. 8 indexed citations

15.

Pang, Juanita, Justin Penner, Matthew Parker, et al.. (2021). Evolution of viral variants in remdesivir‐treated and untreated SARS‐CoV‐2‐infected pediatrics patients. Journal of Medical Virology. 94(1). 161–172. 14 indexed citations

16.

Grandjean, Louis, Anja Saso, Arturo Fraile Torres, et al.. (2020). Long-Term Persistence of Spike Antibody and Predictive Modeling of Antibody Dynamics Following Infection with SARS-CoV-2. SSRN Electronic Journal. 2 indexed citations

17.

Best, Timothy, Dalin Li, Andrew D. Skol, et al.. (2011). Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma. Nature Medicine. 17(8). 941–943. 116 indexed citations

18.

Doçi, Colleen L., Alexander Langerman, Kelly R. Ostler, et al.. (2011). Characterization of NOL7 Gene Point Mutations, Promoter Methylation, and Protein Expression in Cervical Cancer. International Journal of Gynecological Pathology. 31(1). 15–24. 10 indexed citations

19.

Farini, R, Carlo Fabris, G. Del Favero, et al.. (1981). Role of Trypsin/Creatinine Clearance Ratio in the Differential Diagnosis of Chronic Pancreatic Disease. Gastroenterology. 81(2). 242–246. 11 indexed citations

20.

Best, Timothy & M. H. Finlayson. (1979). Two forms of encephalitis in opportunistic toxoplasmosis.. PubMed. 103(13). 693–6. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact